OS Therapies Announces FDA OST-HER2 Type D Meeting Elevated to Type B Pre-BLA Meeting
FDA's elevated meeting status signals transition from biomarker data discussions to Accelerated Approval discussions OS Therapies Inc. (NYSE:OSTX) NEW YORK, NY, UNITED STATES, March 10, 2026 /EINPresswire.com/ -- OS Therapies Inc. (NYSE American: …